Acumen Pharmaceuticals (ABOS) Share-based Compensation (2020 - 2026)

Acumen Pharmaceuticals has disclosed Share-based Compensation across 7 years of filings, most recently posting $2.5 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 1.04% year-over-year to $2.5 million; the TTM figure through Jun 2026 stood at $9.8 million (up 1.52% YoY), while the FY2025 annual figure was $9.9 million, up 2.25% from the prior year.
• Share-based Compensation came in at $2.5 million for Q2 2026 at Acumen Pharmaceuticals, up from $2.4 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $2.5 million in Q2 2026 to a low of $618000.0 in Q1 2022.
• Average Share-based Compensation over 5 years is $1.9 million, with a median of $2.3 million recorded in 2024.
• Year-over-year, Share-based Compensation surged 462.99% in 2022 and slipped 3.15% in 2026.
• Over 5 years, Share-based Compensation stood at $888000.0 in 2022, then jumped by 84.01% to $1.6 million in 2023, then soared by 43.39% to $2.3 million in 2024, then advanced by 3.24% to $2.4 million in 2025, then advanced by 4.34% to $2.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $2.5 million in Q2 2026, $2.4 million in Q1 2026, and $2.4 million in Q4 2025.